3.42% -0.0352

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc 주식(ONCT)의 최신 뉴스

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc 주식(ONCT)의 최신 뉴스

Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World

Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808 - CGTLive™

Oncternal Therapeutics (NASDAQ:ONCT) Downgraded by Northland Capmk - Defense World

Oncternal stock crashes by 60% as it lays off staff and scraps trials - Pharmaceutical Technology

Oncternal stock crashes by 60% as it lays off staff and scraps trials - Clinical Trials Arena

Oncternal stock crashes by 60% as it lays off staff and scraps trials - Yahoo Finance

Analyzing the Impact of Earnings Reports on Oncternal Therapeutics Inc Inc. (ONCT) Price Performance - The InvestChronicle

Director Wills Robert James acquire 3,086 shares of Oncternal Therapeutics Inc [ONCT] - Knox Daily

In the Green: Oncternal Therapeutics Inc (ONCT) Closes at 1.70, Up/Down -59.09 from Previous Day - The Dwinnex

Oncternal plunges on portfolio shakeup - MSN

Denali Therapeutics Inc [DNLI] stock for 77,007 USD was sold by SATO VICKI L - Knox Daily

Oncternal Therapeutics announces workforce reduction and trial discontinuations - Investing.com

Oncternal Therapeutics Cuts Jobs, Discontinues Product Development Amid Business Review - MarketWatch

Oncternal Therapeutics Restructures Amid Clinical Setbacks - TipRanks

Oncternal stock plunges on portfolio shakeup (NASDAQ:ONCT) - Seeking Alpha

Oncternal halts trials for cancer treatments, seeks alternatives - Investing.com

Oncternal Therapeutics Ends Development Activities, Mulls Options - MarketWatch

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives - GlobeNewswire

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives - Yahoo Finance

Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World

Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com - Defense World

ONCT (Oncternal Therapeutics) Financial Strength : 8 (As of Jun. 2024) - GuruFocus.com

Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $18.00 at HC Wainwright - Defense World

Oncternal Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript - Seeking Alpha

Oncternal Therapeutics: Q2 Earnings Snapshot - CTPost

Oncternal Therapeutics: Q2 Earnings Snapshot - Houston Chronicle

Oncternal Therapeutics: Q2 Earnings Snapshot - New Haven Register

Oncternal Therapeutics: Q2 Earnings Snapshot - CT Insider

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates - MSN

Oncternal Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - BioSpace

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Oncternal Therapeutics: Q2 Earnings Snapshot - Danbury News Times

Oncternal Therapeutics: Q2 Earnings Snapshot - The Bakersfield Californian

Oncternal Therapeutics (NASDAQ:ONCT) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - GlobeNewswire

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - StockTitan

Oncternal Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News

Oncternal Therapeutics (ONCT) Scheduled to Post Quarterly Earnings on Thursday - Defense World

ROR1 in Focus as a target for ADC-based treatments: Recent Developments and Industry ChallengesPart III - geneonline

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com - Defense World

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - GlobeNewswire

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - StockTitan

HC Wainwright Reiterates Buy Rating for Oncternal Therapeutics (NASDAQ:ONCT) - Defense World

When the Price of (ONCT) Talks, People Listen - Stock Traders Daily

Oncternal Announces Enrollment Completed and Dosing - GlobeNewswire

Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - StockTitan

StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - American Banking and Market News

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - StockTitan

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - GlobeNewswire

Metastatic Prostate Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight - GlobeNewswire

(ONCT) Technical Pivots with Risk Controls - Stock Traders Daily

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference - Quantisnow

StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World

Oncternal (ONCT) Down on Restructuring Plan to Extend Runway - Yahoo Singapore News

StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation - Simply Wall St

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World

Oncternal Therapeutics (NASDAQ:ONCT) Receives “Buy” Rating from HC Wainwright - Defense World

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT ... - GlobeNewswire

ONCT과 유사한 종목